Henrik Olsen
Corporate Officer/Principal chez Gliknik, Inc.
Profil
Henrik S.
Olsen is currently working as Vice President-Drug Discovery at Gliknik, Inc. He previously worked as a Scientist at Human Genome Sciences, Inc. He completed his undergraduate degree from the University of Aarhus.
Postes actifs de Henrik Olsen
| Sociétés | Poste | Début |
|---|---|---|
Gliknik, Inc.
 Gliknik, Inc. Pharmaceuticals: MajorHealth Technology Gliknik, Inc. discovers and develops biotechnology drugs for autoimmune diseases and cancer. The company was founded by David S. Block and Scott E. Strome in 2007 and is headquartered in Baltimore, MD. | Corporate Officer/Principal | - |
Anciens postes connus de Henrik Olsen
| Sociétés | Poste | Fin |
|---|---|---|
Human Genome Sciences, Inc.
 Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Directeur Technique/Scientifique/R&D | - |
Formation de Henrik Olsen
| University of Aarhus | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Gliknik, Inc.
Gliknik, Inc. Pharmaceuticals: MajorHealth Technology Gliknik, Inc. discovers and develops biotechnology drugs for autoimmune diseases and cancer. The company was founded by David S. Block and Scott E. Strome in 2007 and is headquartered in Baltimore, MD. | Health Technology |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |
